May 7 (Reuters) - Gilead Sciences ( GILD ) announced $11

billion in new planned investment in the U.S. to add to its

domestic manufacturing and research heft, becoming the latest

company to announce spending plans in reaction to President

Donald Trump's tariff policy.

The new investments, unveiled on Wednesday, will supplement

an already planned spending of $21 billion to boost U.S.

manufacturing and research and development through 2030, the

drugmaker said.

These investments will be used for new technology, building

three new facilities and upgrading three existing sites, it

said.

Major U.S. drugmakers, including Eli Lilly ( LLY ), Johnson

& Johnson ( JNJ ), Merck ( MRK ) and Bristol Myers Squibb ( BMY )

, have also recently announced additional investments to

boost domestic production amid the tariff threat.

The Trump administration has been putting pressure on U.S.

drugmakers to move their medicine production to the country and

announced probes into drug imports that set the stage for levies

in the sector.

On Monday, Trump issued an executive order aimed at easing

the regulatory burden in the U.S. for producing drugs and said

he would make an announcement on the tariffs in the next two

weeks.

Gilead said the additional $11 billion would lead to at

least 800 new direct jobs and support more than 2,200 indirect

jobs by 2028.

The company said its investments would create $43 billion in

value to the U.S. economy over the next five years.